Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response.
about
Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments.Ustekinumab for the treatment of psoriatic arthritis: an updateSecukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.Psoriasis: to treat or to manage?Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective.Treatment of psoriasis with etanercept: the typical patient profile.Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis.Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium).Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy.Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.Defining and characterizing sustained remission in patients with rheumatoid arthritis.Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value.Old and New Biological Therapies for Psoriasis.Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.Secukinumab shows reassuring low immunogenicity.
P2860
Q33641909-F516500A-7446-48DD-AF61-1D6D39B6B42CQ34154247-ACED9D64-53B7-495B-B06A-DB7B938DCA64Q37138974-4ED6D882-C9AD-424F-9799-3E29CB74639AQ37517101-60F9B901-4B49-486F-9798-01D3909D9B3DQ38210780-4E92D08A-F5B7-4A42-B95A-8BFCD6498380Q38537167-C245BBC0-36A5-4544-B4CD-A8AEA6B93169Q38594683-A077D38A-58A5-4F68-B4FC-62B1D6E06854Q38807058-11CFBFD2-A27A-4593-9A79-C8BEFF4F9DEBQ38838470-14497F7E-B559-4B6A-BC8A-C4BE2D141E04Q38895147-D0F024BE-1CBF-464D-9E2D-FEB501CC786FQ40045451-7C33419C-9D26-445D-9109-830468EC818DQ40686340-AC74DA79-9149-422A-9427-379856F6A181Q41861093-9929A0AE-1658-4FF6-B134-A15E082DBA22Q44581266-D65868FF-BA10-4933-9B61-71520010C842Q47336584-EB27F147-5553-44C8-96EA-4E70CB84A353Q47737814-AD27C206-97A6-4BDC-AA6E-D22F0BC76333Q47859049-23A91B97-B550-4DC2-8435-CA2E1BEC878AQ50214755-06118379-0E51-4696-B03E-C166ABB7A4C2Q51097419-9E4BC5B3-92EB-41C8-86C2-AB4801F50AFE
P2860
Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anti-drug antibodies in psoria ...... impact on treatment response.
@en
type
label
Anti-drug antibodies in psoria ...... impact on treatment response.
@en
prefLabel
Anti-drug antibodies in psoria ...... impact on treatment response.
@en
P2860
P1476
Anti-drug antibodies in psoria ...... impact on treatment response.
@en
P2093
April W Armstrong
Leeyen Hsu
P2860
P304
P356
10.1586/1744666X.2013.836060
P577
2013-10-01T00:00:00Z